Molecular dissection of HBV evasion from restriction factor tetherin: A new perspective for antiviral cell therapy

Oncotarget

Volumn 6, Issue 26, 2015, Pages 21840-21852

  Miyakawa, Kei ^a   Matsunaga, Satoko ^a   Watashi, Koichi ^b   Sugiyama, Masaya ^c   Kimura, Hirokazu ^b   Yamamoto, Naoki ^d   Mizokami, Masashi ^c   Wakita, Takaji ^b   Ryo, Akihide ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c 1 7 1 Kohnodai   (Japan)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Hepatic injury; Immune response; Immunity; Immunology and microbiology section; Pyroptosis

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; TETHERIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; ANTIVIRUS AGENT; BST2 PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; INTERFERON; LEUKOCYTE ANTIGEN;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; BINDING AFFINITY; CELL MEDIATED CYTOTOXICITY; CELL THERAPY; CELL VIABILITY; CONTROLLED STUDY; DIMERIZATION; HEPATITIS B VIRUS; HOST RESISTANCE; HUMAN; HUMAN CELL; LIVER CELL; MOLECULAR CLONING; NONHUMAN; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; VIRUS IMMUNITY; VIRUS INHIBITION; DRUG EFFECTS; HEK293 CELL LINE; HEP-G2 CELL LINE; HEPATITIS B, CHRONIC; IMMUNOLOGY; VIROLOGY;

ANTIGENS, CD; ANTIVIRAL AGENTS; GPI-LINKED PROTEINS; HEK293 CELLS; HEP G2 CELLS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATOCYTES; HUMANS; INTERFERON TYPE I;

EID: 84941247998     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4808     Document Type: Article

References (44)

1. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nature reviews Immunology. 2014; 14:36-49.
2. Goubau D, Deddouche S, Reis e Sousa C. Cytosolic sensing of viruses. Immunity. 2013; 38:855-869.
3. Duggal NK, Emerman M. Evolutionary conflicts between viruses and restriction factors shape immunity. Nature reviews Immunology. 2012; 12:687-695.
4. Dienstag JL. Hepatitis B virus infection. The New England journal of medicine. 2008; 359:1486-1500.
5. Neil SJ. The antiviral activities of tetherin. Current topics in microbiology and immunology. 2013; 371:67-104.
6. Douglas JL, Gustin JK, Viswanathan K, Mansouri M, Moses AV, Fruh K. The great escape: viral strategies to counter BST-2/tetherin. PLoS pathogens. 2010; 6:e1000913.
7. McNatt MW, Zang T, Bieniasz PD. Vpu binds directly to tetherin and displaces it from nascent virions. PLoS pathogens. 2013; 9:e1003299.
8. Lewinski MK, Jafari M, Zhang H, Opella SJ, Guatelli J. Membrane Anchoring by a C-terminal Tryptophan Enables HIV-1 Vpu to Displace Bone Marrow Stromal Antigen 2 (BST2) from Sites of Viral Assembly. The Journal of biological chemistry. 2015; 290:10919-10933.
9. Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P. Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106:2886-2891.
10. Galao RP, Le Tortorec A, Pickering S, Kueck T, Neil SJ. Innate sensing of HIV-1 assembly by Tetherin induces NFkappaB-dependent proinflammatory responses. Cell host & microbe. 2012; 12:633-644.
11. Cocka LJ, Bates P. Identification of alternatively translated Tetherin isoforms with differing antiviral and signaling activities. PLoS pathogens. 2012; 8:e1002931.
12. Tokarev A, Suarez M, Kwan W, Fitzpatrick K, Singh R, Guatelli J. Stimulation of NF-kappaB activity by the HIV restriction factor BST2. Journal of virology. 2013; 87:2046-2057.
13. Kwon H, Lok AS. Hepatitis B therapy. Nature reviews Gastroenterology & hepatology. 2011; 8:275-284.
14. Wu M, Xu Y, Lin S, Zhang X, Xiang L, Yuan Z. Hepatitis B virus polymerase inhibits the interferon-inducible MyD promoter by blocking nuclear translocation of Stat1. The Journal of general virology. 2007; 88:3260-3269.
15. Chen J, Wu M, Zhang X, Zhang W, Zhang Z, Chen L, He J, Zheng Y, Chen C, Wang F, Hu Y, Zhou X, Wang C, Xu Y, Lu M, Yuan Z. Hepatitis B virus polymerase impairs interferon-alpha-induced STAT activation through inhibition of importin-alpha5 and protein kinase C-delta. Hepatology. 2013; 57:470-482.
16. Hiraga N, Imamura M, Hatakeyama T, Kitamura S, Mitsui F, Tanaka S, Tsuge M, Takahashi S, Abe H, Maekawa T, Ochi H, Tateno C, Yoshizato K, Wakita T, Chayama K. Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice. Journal of hepatology. 2009; 51:1046-1054.
17. Watashi K, Sluder A, Daito T, Matsunaga S, Ryo A, Nagamori S, Iwamoto M, Nakajima S, Tsukuda S, Borroto-Esoda K, Sugiyama M, Tanaka Y, Kanai Y, Kusuhara H, Mizokami M, Wakita T. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology. 2013.
18. Miyagi E, Andrew AJ, Kao S, Strebel K. Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106:2868-2873.
19. Mangeat B, Gers-Huber G, Lehmann M, Zufferey M, Luban J, Piguet V. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS pathogens. 2009; 5:e1000574.
20. Perez-Caballero D, Zang T, Ebrahimi A, McNatt MW, Gregory DA, Johnson MC, Bieniasz PD. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell. 2009; 139:499-511.
21. Sakuma T, Sakurai A, Yasuda J. Dimerization of tetherin is not essential for its antiviral activity against Lassa and Marburg viruses. PloS one. 2009; 4:e6934.
22. Iwabu Y, Fujita H, Kinomoto M, Kaneko K, Ishizaka Y, Tanaka Y, Sata T, Tokunaga K. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes. The Journal of biological chemistry. 2009; 284:35060-35072.
23. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife. 2012; 1:e00049.
24. Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Falth M, Stindt J, Koniger C, Nassal M, Kubitz R, Sultmann H, Urban S. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology. 2014; 146:1070-1083.
25. Iwamoto M, Watashi K, Tsukuda S, Aly HH, Fukasawa M, Fujimoto A, Suzuki R, Aizaki H, Ito T, Koiwai O, Kusuhara H, Wakita T. Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP. Biochemical and biophysical research communications. 2014; 443:808-813.
26. Lenhoff RJ, Summers J. Construction of avian hepadnavirus variants with enhanced replication and cytopathicity in primary hepatocytes. Journal of virology. 1994; 68:5706-5713.
27. Baumert TF, Yang C, Schurmann P, Kock J, Ziegler C, Grullich C, Nassal M, Liang TJ, Blum HE, von Weizsacker F. Hepatitis B virus mutations associated with fulminant hepatitis induce apoptosis in primary Tupaia hepatocytes. Hepatology. 2005; 41:247-256.
28. Miao EA, Rajan JV, Aderem A. Caspase-1-induced pyroptotic cell death. Immunological reviews. 2011; 243:206-214.
29. Rayamajhi M, Zhang Y, Miao EA. Detection of pyroptosis by measuring released lactate dehydrogenase activity. Methods Mol Biol. 2013; 1040:85-90.
30. Capobianchi MR, Abbate I, Cappiello G, Solmone M. HCV and interferon: viral strategies for evading innate defence mechanisms in the virus-host battle. Cell death and differentiation. 2003; 10:S22-24.
31. Woltman AM, Op den Brouw ML, Biesta PJ, Shi CC, Janssen HL. Hepatitis B virus lacks immune activating capacity, but actively inhibits plasmacytoid dendritic cell function. PloS one. 2011; 6:e15324.
32. Turelli P, Mangeat B, Jost S, Vianin S, Trono D. Inhibition of hepatitis B virus replication by APOBEC3G. Science. 2004; 303:1829.
33. Mao R, Zhang J, Jiang D, Cai D, Levy JM, Cuconati A, Block TM, Guo JT, Guo H. Indoleamine 2, 3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells. Journal of virology. 2011; 85:1048-1057.
34. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. Journal of hepatology. 2000; 33:998-1002.
35. Lupfer C, Malik A, Kanneganti TD. Inflammasome control of viral infection. Current opinion in virology. 2015; 12:38-46.
36. Wu DL, Xu GH, Lu SM, Ma BL, Miao NZ, Liu XB, Cheng YP, Feng JH, Liu ZG, Feng D, Na L, Li WQ, Zhao YR. Correlation of AIM2 expression in peripheral blood mononuclear cells from humans with acute and chronic hepatitis B. Human immunology. 2013; 74:514-521.
37. Zhen J, Zhang L, Pan J, Ma S, Yu X, Li X, Chen S, Du W. AIM2 mediates inflammation-associated renal damage in hepatitis B virus-associated glomerulonephritis by regulating caspase-1, IL-1beta, and IL-18. Mediators of inflammation. 2014; 2014:190860.
38. Manigold T, Bocker U, Chen J, Gundt J, Traber P, Singer MV, Rossol S. Hepatitis B core antigen is a potent inductor of interleukin-18 in peripheral blood mononuclear cells of healthy controls and patients with hepatitis B infection. Journal of medical virology. 2003; 71:31-40.
39. Sugiyama M, Tanaka Y, Kato T, Orito E, Ito K, Acharya SK, Gish RG, Kramvis A, Shimada T, Izumi N, Kaito M, Miyakawa Y, Mizokami M. Influence of hepatitis B virus genotypes on the intra-and extracellular expression of viral DNA and antigens. Hepatology. 2006; 44:915-924.
40. Kudoh A, Takahama S, Sawasaki T, Ode H, Yokoyama M, Okayama A, Ishikawa A, Miyakawa K, Matsunaga S, Kimura H, Sugiura W, Sato H, Hirano H, Ohno S, Yamamoto N, Ryo A. The phosphorylation of HIV-1 Gag by atypical protein kinase C facilitates viral infectivity by promoting Vpr incorporation into virions. Retrovirology. 2014; 11:9.
41. Miyakawa K, Ryo A, Murakami T, Ohba K, Yamaoka S, Fukuda M, Guatelli J, Yamamoto N. BCA2/Rabring7 promotes tetherin-dependent HIV-1 restriction. PLoS pathogens. 2009; 5:e1000700.
42. Takayama K, Inamura M, Kawabata K, Sugawara M, Kikuchi K, Higuchi M, Nagamoto Y, Watanabe H, Tashiro K, Sakurai F, Hayakawa T, Furue MK, Mizuguchi H. Generation of metabolically functioning hepatocytes from human pluripotent stem cells by FOXA2 and HNF1alpha transduction. Journal of hepatology. 2012; 57:628-636.
43. Miyakawa K, Sawasaki T, Matsunaga S, Tokarev A, Quinn G, Kimura H, Nomaguchi M, Adachi A, Yamamoto N, Guatelli J, Ryo A. Interferon-induced SCYL2 limits release of HIV-1 by triggering PP2A-mediated dephosphorylation of the viral protein Vpu. Science signaling. 2012; 5:ra73.
44. Miyakawa K, Matsunaga S, Kanou K, Matsuzawa A, Morishita R, Kudoh A, Shindo K, Yokoyama M, Sato H, Kimura H, Tamura T, Yamamoto N, Ichijo H, Takaori-Kondo A, Ryo A. ASK1 restores the antiviral activity of APOBEC3G by disrupting HIV-1 Vif-mediated counteraction. Nature communications. 2015; 6:6945.